Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Multiple Intranigral Unilateral LPS Infusion Protocol Generates a Persistent Cognitive Impairment without Cumulative Dopaminergic Impairment

Author(s): Ana Marcia Delattre, Bruno Carabelli, Marco Aurélio Mori, Claudia Pudell, Danielle R.B.L. da Silva, Isabela Menezes, Paula R.G. Kempe, Pedro Vinícius Staziaki, Patrícia A. Dombrowski, Claudio da Cunha, Marcelo M.S. Lima and Anete C. Ferraz

Volume 12 , Issue 7 , 2013

Page: [1002 - 1010] Pages: 9

DOI: 10.2174/18715273113129990074

Price: $65

Abstract

Inflammation in Parkinson’s disease (PD) is a continuous process and might be implicated in the progression of neuronal degeneration. Taking this into account, we proposed a new protocol with multiple and consecutive intranigral lipopolysaccharide (LPS) administration in order to analyze its effects on cognitive behavior. Additionally, striatal concentrations of the neurotransmitters dopamine (DA) and serotonin and their respective metabolites were assessed in three different time-points with the purpose of identifying the consecutive and cumulative effects of LPS infusions. We demonstrated that with a minimum administered dose there was stabilization of neuronal damage as revealed by absence of synergic effect on DA concentration. Although the DA decrease (–43%) generates an animal model of early phase of PD, without apparent motor impairment, the LPS group exhibited deficit in episodic-like memory behavior from the first time-point until the last one, indicating persisted disturbances in memory-recognition responses. These findings provide evidence that multiple intranigral LPS infusions are not sufficient to cause cumulative and progressive damage to dopaminergic neurons, but confirm that the LPS model can be adopted as a useful tool providing insight about the cognitive impairment observed in pre-motor phase of PD.

Keywords: Parkinson’s disease, lipopolysaccharide, cognitive impairment, novel-object recognition test.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy